Identification of Variables Influencing Resistin Serum Levels in Patients with Type 1 and Type 2 Diabetes Mellitus

Abstract

Background: Resistin, a peptide hormone, has been discussed controversially as a missing link between obesity and insulin resistance. In contrast to resistin mRNA expression in adipose tissue, data on human serum levels in obesity and diabetes mellitus is scarce. The physiological range of serum resistin levels, reference values or adjusted percentiles have not yet been determined, making the interpretation of serum resistin concentrations quite difficult. Methods: Resistin serum concentrations were measured systematically by ELISA in 216 healthy controls, 555 patients with type 2 diabetes and 114 patients with type 1 diabetes. Mean values, median, and range were determined, and BMI-, gender-, and disease-adapted percentiles were calculated for all subgroups. Results: Age and gender did not have any influence on resistin levels. BMI and resistin levels were positively correlated in healthy controls (p = 0.02), albeit with a weak correlation coefficient. This correlation was absent in patients with type 1 and type 2 diabetes. In both genders, healthy controls had significantly higher resistin levels than patients with type 1 and type 2 diabetes (7.9 ± 0.2 ng/ml vs. 5.7 ± 0.2 ng/ml and 5.5 ± 0.1 ng/ml, respectively; p < 0.0001). There was no correlation between resistin levels and occurrence of diabetic retinopathy or nephropathy. Conclusions: Serum resistin levels can be measured by ELISA over a broad range from 0.6 ng/ml up to 27.7 ng/ml, suggesting that percentiles might be helpful in the interpretation of an individuals resistin value. While age and gender do not influence resistin levels, BMI and occurrence of diabetes have to be considered.

Key words

Resistin - Diabetes mellitus - Obesity - Adipocytokines

References

• 1 Steppan C M, Brown E J, Wright C M, Bhat S, Banerjee R R, Dai C Y, Enders G H, Silberg D G, Wen X, Wu G D, Lazar M A. A family of tissue-specific resistin-like molecules.  PNAS. 2001;  98 502-506
• 2 Steppan C M, Bailey S T, Bhat S, Brown E J, Banerjee R R, Wright C M, Patel H R, Ahima R S, Lazar M A. The hormone resistin links obesity to diabetes.  Nature. 2001;  409 307-312
• 3 Holcomb I N, Kabakoff R C, Chan B, Baker T W, Gurney A, Henzel W, Nelson C, Lowman H B, Wright B D, Skelton N J, Frantz G D, Tumas D B, Peale F V, Shelton D L, Hebert C C. FIZZ1, a novel cysteine-rich secreted protein associated with pulmonary inflammation, defines a new gene family.  EMBO J. 2000;  19 4046-4055
• 4 Banerjee R R, Lazar M A. Dimerization of resistin and resistin-like molecules is determined by a single cystein.  J Biol Chem. 2001;  276 25 970-25 973
• 5 McTernan C L, McTernan P G, Harte A L, Levick P L, Barnett A H, Kumar S. Resistin, central obesity, and type 2 diabetes.  Lancet. 2002;  359 46-47
• 6 Villena J A, Kim K H, Sul S. Pref-1 and ADSF/Resistin: Two secreted factors inhibiting adipose tissue development.  Horm Metab Res. 2002;  34 664-670
• 7 Steppan C M, Lazar M A. Resistin and obesity-associated insulin resistance.  Trends Endocrinol Metab. 2002;  13 18-23
• 8 Rajala M W, Obici S, Scherer P E, Rosetti L. Adipose-derived resistin and gut-derived resistin-like molecule-beta selectively impair insulin action on glucose production.  J Clin Invest. 2003;  111 225-230
• 9 Vidal-Puig A, O'Rahilly S. Resistin: a new link between obesity and insulin resistance?.  Clin Endocrinol. 2001;  55 437-438
• 10 Way J M, Gorgun C Z, Tong Q, Uysal K T, Brown K K, Harrington W W, Oliver W W, Oliver W R, Willson T M, Kliewer S A, Hotamisligil G S. Adipose tissue resistin expression is severely suppressed in obesity and stimulated by peroxisome proliferator-activated receptor Y agonists.  J Biol Chem. 2001;  276 25651-25653
• 11 Janke J, Engeli S, Gorzelniak K, Luft F C, Sharma A M. Resistin gene expression in human adipocytes is not related to insulin resistance.  Obes Res. 2002;  10 1-5
• 12 Fehmann H C, Heyn J. Plasma resistin levels in patients with type 1 and type 2 diabetes mellitus and in healthy controls.  Horm Metab Res. 2002;  34 671-673
• 13 Yannakoulia M, Yiannakouris N, Bluher S, Matalas A L, Klimis-Zacas C, Mantzoros C S. Body fat mass and macronutrient intake in relation to circulating soluble leptin receptor, free leptin index, adiponectin, and resistin concentrations in healthy humans.  J Clin Endocrinol Metab. 2003;  88 1730-1736
• 14 Lee J H, Chan J L, Yiannakouris N, Kontogianni M, Estrada E, Seip R. et al . Circulating resistin levels are not associated with obesity or insulin resistance in humans and are not regulated by fasting or leptin administration: cross-sectional and interventionals studies in normal, insulin-resistant, and diabetic subjects.  J Clin Endocrinol Metab. 2003;  88 4848-4856
• 15 Pfutzner A, Langenfeld M, Kunt T, Lobig M, Forst T. Evaluation of human resistin assays with serum from patients with type 2 diabetes and different degrees of insulin resistance.  Clin Lab. 2003;  49 571-576
• 16 Azuma K, Katsukawa G, Oguchi S, Murata M, Yamazaki H, Shimada A, Saruta T. Correlation between serum resistin level and adiposity in obese individuals.  Obes Res. 2003;  11 997-1001
• 17 Iglesias P, Alvarez-Fidalgo P, Codoceo T, Diez J J. Serum concentrations of adipocytokines in patients with hyperthyroidism and hypothyroidism before and after control of thyroid function.  Clin Endocrinol. 2003;  59 621-629
• 18 Zietz B, Barth N, Schölmerich J, Schmitz G, Schäffler A. Gly15Gly polymorphism within the human adipocyte-specific apM-1 gene but not Tyr111His polymorphism is associated with higher levels of cholesterol and LDL-cholesterol in caucasian patients with type 2 diabetes.  Exp Clin Endocrin Diab. 2002;  109 320-325
• 19 Zietz B, Herfarth H, Paul G, Ehling A, Müller-Ladner U, Schölmerich H, Schäffler A. Adiponectin represents an independent risk factor predicting serum HDL-cholesterol levels in type 2 diabetes.  FEBS Lett. 2003;  545 103-104
• 20 Schäffler A, Barth N, Palitzsch K D, Schölmerich J, Schmitz G. Mutation analysis of the human adipocyte-specific apM-1 gene.  Europ J Clin Invest. 2000;  30 879-887
• 21 Kohner E M, Porta M. Protocols for screening and treatment of diabetic retinopathy in Europe.  European Journal of Ophthalmology. 1991;  1 45-54